Human Microbiome Project

Human Microbiome Project
Name	Human Microbiome Project
Abbreviation	HMP
Formation	2007
Founder	National Institutes of Health
Purpose	To characterize the human microbiome
Headquarters	Bethesda, Maryland
Region served	United States
Leader title	Lead agency
Leader name	National Human Genome Research Institute
Website	hmpdacc.org

Human Microbiome Project. The Human Microbiome Project was a landmark United States National Institutes of Health initiative launched in 2007. It aimed to comprehensively characterize the microbial communities found in and on the human body and to analyze their role in human health and disease. This large-scale collaborative effort generated an unprecedented reference dataset, fundamentally transforming the field of microbiology and our understanding of human biology.

Background and goals

The project was conceived following the success of the Human Genome Project, which highlighted the need to understand the vast genetic contribution of associated microbial life. Key scientific drivers included advances in DNA sequencing technologies, particularly metagenomics, which allowed for the study of microbial communities without the need for culturing. The primary goals were to determine a core human microbiome, understand its variation across different body sites and individuals, and elucidate the functional roles of these microbes in maintaining health. The initiative was formally funded by the NIH Common Fund and coordinated by the National Human Genome Research Institute.

Methodology and phases

The project employed a multi-phase, multi-institutional approach. The initial phase, HMP1 (2007-2012), focused on generating a comprehensive reference dataset. Researchers collected samples from over 200 healthy volunteers at body sites including the gastrointestinal tract, oral cavity, skin, and vagina. Analysis relied heavily on 16S ribosomal RNA gene sequencing for taxonomic profiling and whole genome shotgun sequencing for metagenomic and metabolic pathway analysis. A second phase, the Integrative Human Microbiome Project (iHMP or HMP2) launched in 2013, shifted to dynamic longitudinal studies of microbiome-associated conditions like inflammatory bowel disease, prediabetes, and preterm birth.

Key findings

The project revealed that the human microbiome is extraordinarily diverse and personalized, yet serves core functional functions. It established that healthy individuals carry thousands of microbial types, with Bacteroidetes and Firmicutes dominating the gut. A major discovery was the existence of functional redundancy, where different microbial communities can perform similar metabolic roles. The data also showed that microbial genes vastly outnumber human genes, and that microbiome composition is influenced by factors like diet, antibiotics, and host genetics. Furthermore, it documented distinct microbial community states associated with health and specific disease conditions.

Impact and applications

The project's impact has been profound, establishing the microbiome as a central factor in human physiology. It catalyzed the growth of the entire field, leading to new research into connections with obesity, autism spectrum disorder, cardiovascular disease, and cancer. Applications have emerged in developing novel diagnostics, probiotics, and targeted therapies like fecal microbiota transplant for recurrent Clostridioides difficile infection. The framework and data have also influenced other major international efforts like the MetaHIT project in Europe and the Earth Microbiome Project.

Data and resources

A cornerstone of the project's legacy is its commitment to open data. All sequence data, protocols, and analysis tools were made publicly available through the Data Analysis and Coordination Center (DACC). Key resources include the Integrated Microbial Genomes system, the Human Microbiome Project Database, and vast repositories hosted at the National Center for Biotechnology Information. These resources continue to serve as a foundational reference for thousands of subsequent studies in academic, clinical, and industrial research settings worldwide.

Criticisms and limitations

Despite its achievements, the project faced several criticisms. The initial phase's focus on a predominantly healthy, U.S.-based cohort limited the understanding of global microbiome diversity and disease states. The reliance on DNA sequencing provided a genetic snapshot but often failed to capture the viability, activity, and complex ecological interactions of microbial communities. Some scientists argued it prioritized cataloging over mechanistic understanding, a gap the later iHMP aimed to address. Ethical questions regarding data privacy and the commercial exploitation of microbiome findings also emerged from the research.

Category:National Institutes of Health Category:Microbiology Category:2007 in science